Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07253116 | A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 20 | Nanjing Jingao biomidical technology Co. Ltd.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT02264613 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 / Phase 2 | 142 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04379518 | Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04773782 | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | completed | Phase 1 / Phase 2 | 29 | Blueprint Medicines CorporationINDUSTRY | 9 | Jan 13, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT07268040 | A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors | recruiting | Phase 2 | 400 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07333664 | Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesions | not yet recruiting | Phase 2 | 120 | Li MinOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06737731 | A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07258160 | Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors | recruiting | Phase 2 | 127 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04284488 | Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT06631079 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 20 | NEC Bio B.VINDUSTRY | 3 | Jan 8, 2026 | clinicaltrials |
| NCT07131202 | A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 130 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07327294 | A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor | not yet recruiting | Phase 1 / Phase 2 | 150 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07327411 | Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04175847 | A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 198 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07321574 | A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors(ABP1011T-03) | recruiting | Phase 2 | 110 | Shanghai AB PharmaTech Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05174585 | JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 21 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05774873 | The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. | completed | Phase 1 / Phase 2 | 28 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05584800 | Study of ZGGS18 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 222 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06938880 | Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07124117 | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | OBI Pharma, IncINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03993678 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 28 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06198426 | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 30, 2025 | clinicaltrials |
| NCT07265622 | First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | not yet recruiting | Phase 1 / Phase 2 | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT03993379 | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | terminated | Phase 2 | 3 | CytomX TherapeuticsINDUSTRY | 5 | Dec 26, 2025 | clinicaltrials |
| NCT05503251 | Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases | active not recruiting | Phase 2 | 110 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07197827 | A Study of YL242 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 424 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 24, 2025 | clinicaltrials |
| NCT06459973 | A Clinical Study of YL205 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 252 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | Dec 23, 2025 | clinicaltrials |
| NCT06712680 | A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes | recruiting | Phase 1 / Phase 2 | 115 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05508334 | A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 41 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07229586 | A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06825494 | Clinical Studies for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 194 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07003321 | A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04349267 | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Bristol-Myers SquibbINDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT05566574 | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer | active not recruiting | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06383884 | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05522491 | Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07274449 | Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors(NK) | active not recruiting | Phase 1 / Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07272590 | Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 290 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 9, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 14, 2026source: clinicaltrials